Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myelomaTorben Plesner, Paul G. Richardson, Hendrik‐Tobias Arkenau et al.|Blood|2016Cited by 110
Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrencesShuling Chen, Ming Kuang, Huanjing Hu et al.|Gut|2023Cited by 66
Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)Torben Plesner, Paul G. Richardson, Hendrik‐Tobias Arkenau et al.|Blood|2015Cited by 40
Transanal total mesorectal excision for rectal cancer: a multicentric cohort studyLiang Kang, Jianping Wang, Yuanguang Chen et al.|Gastroenterology report|2019Cited by 39